Femasys is trading at $3.08, down -5.67%, with no clear catalyst identified.
- No company-specific announcement dated September 2, 2026 appears on Femasys’s investor-relations news page; its latest listed release was August 26.
- The decline follows losses on September 1, while broader U.S. indexes gained roughly 0.5%; recent biotechnology strength does not explain the isolated move.
- The decline remains unattributed pending potential delayed filings or company news.